Wockhardt LimitedNSE: WOCKPHARMA

Press Release Dec 16 2024

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Wockhardt Limited submitted a press release regarding the successful use of Zaynich™ in a US cancer patient, enabling her to undergo a liver transplant after eradicating drug-resistant infections. The treatment was necessary after the patient failed to respond to other antibiotics, highlighting the effectiveness of Zidebactam/Cefepime in critical cases.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Wockhardt Limited has informed the Exchange regarding a press release dated December 16, 2024, titled "Zaynich (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme-drug resistant Gram negative pathogens".

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases